Lymphoproliferative disorders and de novo malignancies in intestinal and multivisceral recipients: Improved outcomes with new outlooks

Transplantation

Volumn 88, Issue 7, 2009, Pages 926-934

  Abu Elmagd, Kareem M ^a   Mazariegos, George ^a   Costa, Guilherme ^a   Soltys, Kyle ^a   Bond, Geoffrey ^a   Sindhi, Rakesh ^a   Green, Michael ^a   Jaffe, Ronald ^a   Wu, Tong ^a   Koritsky, Darlene ^a   Matarese, Laura ^a   Schuster, Bonnie ^a   Martin, Lillian ^a   Dvorchik, Igor ^a   Nalesnik, Michael A ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

De novo malignancy; Intestinal transplantation; Posttransplant lymphoproliferative disorders; Recipient pretreatment with ratg and alemtuzumab

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; DEXAMETHASONE; GANCICLOVIR; HYDROCORTISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADOLESCENT; ADRENAL INSUFFICIENCY; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHILD; DISEASE COURSE; DONOR; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GROUPS BY AGE; HERPES SIMPLEX; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; INTESTINE TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MORBIDITY; MORTALITY; NONLYMPHOID CANCER; ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDERS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE DRUG DOSE; SPLENECTOMY; SURVIVAL RATE; VIRUS LOAD;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANIMALS; ANTILYMPHOCYTE SERUM; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINES; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; NEOPLASMS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RABBITS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; VISCERA;

EID: 73249144808     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b7509c     Document Type: Article

References (44)

1. Todo S, Reyes J, Furukawa H, et al. Outcome analysis of 71 clinical intestinal transplantations. Ann Surg 1995; 222: 270.
2. Abu-Elmagd K, Reyes J, Todo S, et al. Clinical intestinal transplantation: New perspectives and immunologic considerations. J Am Coll Surg 1998; 186: 512.
3. Grant D, Abu-Elmagd K, Reyes J, et al. 2003 Report of the Intestinal Transplant Registry: A New Era Has Dawned. Ann Surg 2005; 241: 607.
4. Abu-Elmagd K.M., Zak M, Stamos J, et al. De novo malignancies after intestinal and multivisceral transplantation. Transplantation 2004; 15: 1719.
5. Green M, Reyes J, Rowe D. New strategies in the prevention and management of Epstein-Barr virus infection and posttransplant lymphoproliferative disease following solid organ transplantation. Curr Opin Organ Transplant 1998; 3: 143.
6. Abu-Elmagd K, Reyes J, Bond G, et al. Clinical intestinal transplantation: A decade of a single center experience. Ann Surg 2001; 234: 404.
7. Starzl TE, Murase N, Abu-Elmagd K, et al. Tolerogenic immunosuppression for organ transplantation. Lancet 2003; 361: 1502.
8. Abu-Elmagd K, Fung J, McGhee W, et al. The efficacy of daclizumab for intestinal transplantation: Preliminary report. Transplant Proc 2000; 32: 1195.
9. Abu-Elmagd KM, Costa G, Bond GJ, et al. Evolution of the immunosuppression strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance. Transpl Int 2008; 22: 96.
10. Fontes P, Rao AS, Demetris AJ, et al. Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet 1994; 344: 151.
11. Murase N, Ye Q, Nalesnik MA, et al. Immunomodulation for intestinal transplantation by allograft irradiation, adjunct donor bone marrow infusion, or both. Transplantation 2000; 70: 1632.
12. Abu-Elmagd K, Todo S, Tzakis A, et al. Three years clinical experience with intestinal transplantation. J Am Coll Surg 1994; 179: 385.
13. Abu-Elmagd KM, Bond G, Reyes J, et al. Intestinal transplantation: A coming of age. Adv Surg 2002; 36: 65.
14. Green M, Bueno J, Rowe D, et al. Predictive negative value of persistent low EBV viral load after intestinal transplantation in children. Transplantation 2000; 70: 593.
15. Wadowsky RM, Laus S, Green M, et al. Measurement of Epstein-Barr virus DNA loads in whole blood and plasma by TaqMan PCR and in peripheral blood lymphocytes by competitive PCR. J Clin Microbiol 2003; 41: 5245.
16. Nato JS, Macedo C, Jaffe R, et al. Carcinoma of donor origin after liverintestine transplantation in a child. Pediatr Transplant 2005; 9: 244.
17. Todo S, Tzakis AG, Abu-Elmagd K, et al. Intestinal transplantation in composite visceral grafts or alone. Ann Surg 1992; 216: 223.
18. McDiarmid SV, Stan J, Lee GS, et al. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604.
19. Dharnidharka VR, Araya CE. Post-transplant lymphoproliferative disease. Pediatr Nephrol 2009; 24: 731.
20. Leblond V, Choquet S. Lymphoproliferative disorders after liver transplantation. J Hepatol 2004; 40: 728.
21. Kremers WK, Devarbhavi HC, Wiesner RH, et al. Post-transplant lymphoproliferative disorders following liver transplantation: Incidence, risk factors and survival. Am J Transplant 2006; 6: 1017.
22. Fung JJ, Jain A, Kwak EJ, et al. De novo malignancies after liver transplantation: A major cause of late death. Liver Transplant 2001; 7: S109.
23. Wasson S, Zafar MN, Best J, et al. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: A single-center experience. J Cardiovasc Pharmacol Therapeut 2006; 11: 77.
24. Ziarkiewicz-Wroblewska B, Gornicka B, Suleiman W, et al. Posttransplant lymphoproliferative disorder: Morphological picture and diagnostic difficulties. Transplant Proc 2006; 38: 168.
25. Roque J, Rios G, Humeres R et al. Early posttransplant lymphoproliferative disease in pediatric liver transplant, recipients. Transplant Proc 2006; 38: 930.
26. Abu-Elmagd K, Reyes J, Fung JJ. Transplantation of the human intestine: The forbidden organ. Curr Opin Organ Transplant 1998; 3: 286.
27. Starzl TE, Demetris AJ, Murase N, et al. Cell migration, chimerism, and graft acceptance. Lancet 1992; 339: 1579.
28. Iwaki Y, Starzl TE, Yagihashi A, et al. Replacement of donor lymphoid tissue in human small bowel transplants under FK 506 immunosuppression. Lancet 1991; 337: 818.
29. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80(2S): S254.
30. Lai YC, Ni YH, Jou ST, et al. Post-transplantation lymphoproliferative disorders localizing to the gastrointestinal tract after liver transplantation: Report of five pediatric cases. Pediatr Transplant 2006; 10: 390.
31. Abu-Elmagd K. The history of intestinal transplantation. In: Hakim NS, Papalois VE, eds. The History of Organ and Cell Transplantation. Imperial College Press, London, 2003, p 171.
32. Starzl TE, Rowe MI, Todo S, et al. Transplantation of multiple abdominal viscera. JAMA 1989; 261: 1449.
33. Abu-Elmagd KM. Preservation of the native spleen, duodenum, and pancreas in patients with multivisceral transplantation: Nomenclature, dispute of origin, and proof of premise. Transplantation 2007; 84: 1208.
34. Yao FY, Gautam M, Palese C, et al. De novo malignancies following liver transplantation: A case-control study with long-term follow-up. Clin Transplant 2006; 20: 617.
35. Baccarani U, Adani GL, Montanaro D, et al. De novo malignancies after kidney and liver transplantations: Experience on 582 consecutive cases. Transplant Proc 2006; 38: 1135.
36. Herrero JI, Espana A, Quiroga J, et al. Nonmelanoma skin cancer after liver transplantation. Study of risk factors. Liver Transplant 2005; 11: 1100.
37. Roithmaier S, Haydon AM, Loi S, et al. Incidence of malignancies in heart and/or lung transplant recipients: A single-institution experience. J Heart Lung Transplant 2007; 26: 845.
38. Popov Z, Ivanovski O, Kolevski P, et al. De novo malignancies after renal transplantation - A single-center experience in the Balkans. Transplant Proc 2007; 39: 2589.
39. Aseni P, Vertemati M, De Carlis L, et al. De novo cancers and posttransplant lymphoproliferative disorder in adult liver transplantation. Pathol Int 2006; 56: 712.
40. Strazzabosco M, Corneo B, Iemmolo RM, et al. Epstein-Barr virusassociated post-transplant lymphoproliferative disease of donor origin in liver transplant recipients. J Hepatol 1997; 26: 926.
41. Rehbinder B, Wullstein C, Bechstein WO, et al. Epstein-Barr virusassociated posttransplant lymphoproliferative disorder of donor origin after simultaneous pancreas-kidney transplantation limited to pancreas allograft: A case report. Am J Transplant 2006; 6: 2506.
42. Rivet J, Moreau D, Daneshpouy M, et al. T-cell lymphoma with eosinophilia of donor origin occurring 12 years after allogeneic bone marrow transplantation for myeloma. Transplantation 2001; 72: 965.
43. Armes JE, Angus P, Southey MC, et al. Lymphoproliferative disease of donor origin arising in patients after orthotopic liver transplantation. Cancer 1994; 74: 2436.
44. Heyny-von Haussen R, Klingel K, Werner R, et al. Posttransplant lymphoproliferative disorder in a kidney-pancreas transplanted recipient: Simultaneous development of clonal lymphoid B-cell proliferation of host and donor origin. Am J Surg Pathol 2006; 30: 900.